Technology Connects Lab-Discarded Specimens with Researchers; Provides Labs New Revenue

Email not displaying correctly?
View it in your browser.
G2 LogoLab and Pathology Insider Logo
 
May 19, 2015

Sequencing to Target Pancreatic Cancer Tx 'Challenging' in Real World

By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies

Real-world application of sequencing for targeting pancreatic cancer treatment remains challenging, according to a study published in Clinical Cancer Research and presented at the American Association for Cancer Research annual meeting (Philadelphia, April 18-22). Insufficient or nonexistent biopsy samples and slow turnaround times were among the…

Read more...


FDA Approves Roche's KRAS Mutation Test

By Stephanie Murg, Managing Director, G2 Intelligence

Roche's portfolio of companion diagnostics now includes a test that can help clinicians to tailor treatment for patients with metastatic colorectal cancer. The U.S. Food and Drug Administration has approved the company's Cobas KRAS Mutation Test for diagnostic use. The real-time PCR-based test is designed to…

Read more...



Technology Connects Lab-Discarded Specimens with Researchers; Provides Labs New Revenue

By Kelly A. Briganti, Editorial Director, G2 Intelligence

Technology is making use of hospital and laboratory specimens that would otherwise be discarded by connecting those specimen sources with biomedical researchers. iSpecimen (Lexington, Mass.), founded in 2009, links researchers with specimens from participating health care organizations and announced a new technology this month that uses its cloud-based platform, de-identified electronic medical record data and big data analytics to customize and increase the speed of that process…

Read more...


Rosetta Genomics Introduces Two New Bladder Cancer Tests

By Ron Shinkman, Editor, Laboratory Industry Report

Rosetta Genomics has announced two new molecular tests for detecting bladder cancer.
Both urine-based tests focus on mutations within the FGFR3 gene. One test performs monitoring in order to determine if there have been recurrences of a prior bladder cancer. The other works in conjunction with the Ki67 expression of FGFR3 to provide a prognosis and…

Read more...


EMR-Link from Liaison Healthcare is a cloud-based outreach solution for ordering and receiving laboratory and radiology tests and results. It integrates your lab with any EHR system, deploys rapidly, streamlines the lab-ordering and results-review workflows, creates clean and complete lab orders, and sends patient-friendly lab reports. EMR-Link is live at over 1000 practices and supports over 20,000 clinicians and 140 labs. For more information, visit www.liaisonhealthcare.com or call 888.806.0309 (Option #1).


Follow on Twitter  Forward to Friend 

For questions concerning delivery of this email, please contact customer service at: (888) 729-2315 | customerservice@plainlanguagemedia.com

Copyright © 2015, All rights reserved.
Plain Language Media LLLP
PO Box 509
New London, CT
06320